Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357850 · ClinicalTrials.gov registry record · Phase 2
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
A Phase 2 study of Heart Failure, Congestive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 15
- Study locations
NCT01357850 is a Phase 2 study of Heart Failure, Congestive that has completed, run by GlaxoSmithKline. The registered enrollment target is 82 participants, below the 639-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (87% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT01357850, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 15
- Study locations
Study Summary
This exploratory proof of concept study will be conducted in patients with stable New York Heart Association (NYHA) Class II-III heart failure. The focus of the efficacy endpoints is to test the hypothesis that GSK716155 administration will increase glucose uptake and utilization in the myocardium, resulting in increased myocardial efficiency and increased exercise capacity. A positive result, defined as either statistically significant effects on one or more of the efficacy endpoints or as an overall signal suggesting a clinically relevant effect on myocardial physiology, would provide evidence for potential progression into further development in a chronic heart failure population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK716155
Study Locations (15)
Pennsylvania
- GSK Investigational Site - New York
- GSK Investigational Site - Philadelphia
Other
- GSK Investigational Site - London
- GSK Investigational Site - Oxford
Georgia
- GSK Investigational Site - Savannah
Louisiana
- GSK Investigational Site - Metairie
Maine
- GSK Investigational Site - Auburn
Maryland
- GSK Investigational Site - Baltimore
Michigan
- GSK Investigational Site - Detroit
Minnesota
- GSK Investigational Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2010-09-15 |
| Est. Completion | 2012-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357850
The ClinicalTrials.gov registry entry for NCT01357850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (87% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01357850 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT01357850 about?
NCT01357850 is a clinical study titled "A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure". This exploratory proof of concept study will be conducted in patients with stable New York Heart Association (NYHA) Class II-III heart failure. The focus of the efficacy endpoints is to test the hypothesis that GSK716155 administration will increase glucose uptake and utilization in the myocardium, ...
What is the current status of trial NCT01357850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2010-09-15. Estimated completion is 2012-09-18.
What conditions does trial NCT01357850 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT01357850?
The interventions under investigation include: Placebo (DRUG), GSK716155 (DRUG).
Who is sponsoring clinical trial NCT01357850?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357850 being conducted?
This trial has 15 study locations across Georgia, Louisiana, Maine, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise After an ICD
COMPLETED · Phase 2
-
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
COMPLETED · Phase 2
-
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
COMPLETED · Phase 2
-
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
COMPLETED · Phase 2
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.